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Abstract
Inherited retinal degenerations cause progressive loss of photoreceptor neurons with eventual blindness.
Corrective or neuroprotective gene therapies under development could be delivered at a predegeneration
stage to prevent the onset of disease, as well as at intermediate-degeneration stages to slow the rate of
progression. Most preclinical gene therapy successes to date have been as predegeneration interventions. In
many animal models, as well as in human studies, to date, retinal gene therapy administered well after the
onset of degeneration was not able to modify the rate of progression even when successfully reversing
dysfunction. We evaluated consequences of gene therapy delivered at intermediate stages of disease in a
canine model of X-linked retinitis pigmentosa (XLRP) caused by a mutation in the Retinitis Pigmentosa
GTPase Regulator (RPGR) gene. Spatiotemporal natural history of disease was defined and therapeutic dose
selected based on predegeneration results. Then interventions were timed at earlier and later phases of
intermediate-stage disease, and photoreceptor degeneration monitored with noninvasive imaging,
electrophysiological function, and visual behavior for more than 2 y. All parameters showed substantial and
significant arrest of the progressive time course of disease with treatment, which resulted in long-term
improved retinal function and visual behavior compared with control eyes. Histology confirmed that the
human RPGR transgene was stably expressed in photoreceptors and associated with improved structural
preservation of rods, cones, and ON bipolar cells together with correction of opsin mislocalization. These
findings in a clinically relevant large animal model demonstrate the long-term efficacy of RPGR gene
augmentation and substantially broaden the therapeutic window for intervention in patients with RPGR-
XLRP.
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Inherited retinal degenerations cause progressive loss of photore-
ceptor neurons with eventual blindness. Corrective or neuro-
protective gene therapies under development could be delivered
at a predegeneration stage to prevent the onset of disease, as well
as at intermediate-degeneration stages to slow the rate of progres-
sion. Most preclinical gene therapy successes to date have been as
predegeneration interventions. In many animal models, as well as in
human studies, to date, retinal gene therapy administered well
after the onset of degeneration was not able to modify the rate
of progression even when successfully reversing dysfunction. We
evaluated consequences of gene therapy delivered at intermediate
stages of disease in a canine model of X-linked retinitis pigmentosa
(XLRP) caused by a mutation in the Retinitis Pigmentosa GTPase
Regulator (RPGR) gene. Spatiotemporal natural history of disease
was defined and therapeutic dose selected based on predegen-
eration results. Then interventions were timed at earlier and later
phases of intermediate-stage disease, and photoreceptor degen-
eration monitored with noninvasive imaging, electrophysiological
function, and visual behavior for more than 2 y. All parameters
showed substantial and significant arrest of the progressive time
course of disease with treatment, which resulted in long-term im-
proved retinal function and visual behavior compared with control
eyes. Histology confirmed that the human RPGR transgene was
stably expressed in photoreceptors and associated with improved
structural preservation of rods, cones, and ON bipolar cells together
with correction of opsin mislocalization. These findings in a clinically
relevant large animal model demonstrate the long-term efficacy of
RPGR gene augmentation and substantially broaden the therapeutic
window for intervention in patients with RPGR-XLRP.
retinal degeneration | gene therapy | late stage | XLRP | RPGR
The prevalence of neurodegenerative disorders worldwide hasbeen projected to continue to rise dramatically. This situation is
particularly true in developed countries that have seen an increase
in the aging population coupled with a decline in common fatal
conditions, such as stroke and heart attack (1). Chronic and de-
bilitating neurodegenerative diseases impose a huge emotional,
medical, and economical burden on patients, caregivers, and society
(2, 3). Thus, treating neurodegenerations is one of the greatest
scientific challenges taken up with the launch of the Brain Research
through Advancing Innovative Neurotechnologies (BRAIN) Initia-
tive in the United States and the Human Brain Project in Europe.
Decades of research have increased our knowledge of the path-
ogenic mechanisms of neurodegenerative diseases and led to the
identification of potential molecular targets (4); however, the
considerable resources invested in the development of new treat-
ments have achieved only limited success (5). The lack of efficacy
in clinical trials of novel therapies for Alzheimer’s disease (6),
Parkinson’s disease (7), and amyotrophic lateral sclerosis (8) that
appeared promising in preclinical studies has led to questions re-
garding the predictive validity of currently used animal models (9).
Failures can result either because the experimental model does
not recapitulate the human disease or because therapies are de-
veloped in animal models treated successfully at predegeneration
stages as opposed to the intermediate- and advanced-degeneration
stages found in most patients enrolled in clinical trials (Fig. 1A).
The retina, with its remarkable layered organization of inter-
connected neurons and its accessibility to imaging and functional
studies, offers a “window” to the CNS (10). Novel insights into
neurodegenerative processes have originated from the study of
specific blinding ocular conditions such as glaucoma, age-related
macular degeneration, and various inherited retinal degenera-
tions, which include retinitis pigmentosa (RP). RP is a group of
diseases that typically cause progressive degeneration of rod and
cone photoreceptor cells and result in blindness. Over the last
decades, preclinical evidence supporting the initiation of clinical
trials of corrective gene therapy for RP has been based on suc-
cessful proof of concept studies in which therapies were delivered
before degeneration (11) or in models without a degenerative
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component (12–15). These experimental conditions fail to reca-
pitulate the cellular and molecular environment of diseased pho-
toreceptors in patients who have a complex spatial distribution of
stages of disease across the retina (Fig. 1B). Considering the cur-
rent evidence showing the difficulty to stop retinal degeneration
(16, 17), it is of paramount importance to assess the efficacy of new
therapies in more advanced disease stages.
X-linked RP caused by mutation in the Retinitis Pigmentosa
GTPase Regulator (RPGR) gene is one of the most common
inherited retinal degenerations (18–20). There are currently more
than 300 distinct mutations (rpgr.hgu.mrc.ac.uk/supplementary/)
identified in RPGR, and the majority are found in a glutamic acid-
rich domain within exon ORF15 (21, 22). The natural course of
RPGR-XLRP disease is severe, with males showing loss of night
vision in the first decade of life (23). The disease onset in the
naturally occurring or RpgrKOmouse models is very late (23–25) as
it corresponds to 35 human years (26), whereas the disease onset in
two naturally occurring canine models of RPGR-XLRP (27–29) are
earlier and correspond better to the human disease time course.
Gene augmentation delivered by means of an adeno-associated
viral (AAV) vector has been shown to be efficient in both the dog
and mouse models (30, 31). Here we focused on using gene therapy
to treat the intermediate disease stage of RPGR-XLRP in a canine
model, at a time when ∼40% (mid stage) to 60% (late stage) of the
neurons have already been lost to degeneration. We demonstrate
efficacy in arresting further neurodegeneration with reversal of the
photoreceptor disease, and retention of vision, lasting for more than
2 y. These results augur well for potential clinical treatment trials
involving RPGR-XLRP patients who have substantial retinal de-
generation but still retain some photoreceptors and suggest there is
validity in treating and evaluating animals with mid-/late-course
disease in other neurodegenerative disorders.
Results
Spatiotemporal Progression of Retinal Degeneration in Vivo. Muta-
tions in the RPGR gene cause a severe and early-onset form of
progressive retinal degeneration in humans and dogs (30). Of the
two naturally occurring canine diseases, XLPRA2 is caused by a
two-nucleotide deletion within ORF15 that results in a frameshift
and truncation of the terminal 161 amino acid residues. Histolog-
ically, the outer (photoreceptor) nuclear layer (ONL) has a normal
thickness (∼10–11 rows of nuclei) at 5 wk of age that corresponds
to the age of onset of degeneration (29). The rate of photoreceptor
neuronal death initially accelerates with a peak at ∼7 wk of age
before returning to a reduced, yet constant, rate thereafter (29).
The result is a rapid ONL thinning that leads to a thickness of
approximately three rows of nuclei (∼30% of normal) (32) by ∼40 wk
of age (29). In preparation for gene therapy strategies aimed at
positively altering the natural history of the retinal degeneration,
we first used in vivo imaging methods to evaluate the spatial dis-
tribution and temporal progression of ONL thickness changes with
age. WT dogs show an ONL thickness distribution that peaks in the
superior-central retina (Fig. 2A, Left) except for the small highly
cone enriched fovea-like area (33) (Fig. S1 A and B). ONL
thickness in XLPRA2 dogs can progress from near-normal at 8 wk
to severe retina-wide thinning at 95 wk (Fig. S1C). Measurements
at superior, supero-nasal, and inferior retinal locations show a
regular and predictable pattern of ONL thinning with progression
rates of −0.33 log10/y for superior and supero-nasal retinal regions
and −0.45 log10/y for inferior retinal regions. These invariant log-
linear periods of progression last to ∼78 wk of age. Thereafter, a
slowing of the progression rate is apparent with an increase in mea-
surement variability associated with severely thinned ONL (Fig. S1D
and E), reaching the axial resolution limit of the imaging system.
Dose–Response Function for Subretinal Gene Therapy. Subretinal gene
therapy at initial stages of XLPRA2 disease, before detectable
ONL thinning, can arrest the progressive retinal degeneration
(30); however, the dose–response function of the treatment effi-
cacy is not known. To determine the minimum effective titer
(MET), we injected eight eyes at the onset of degeneration (5 wk
of age) with over a 2.5 log10 range of titers, and used as a principal
outcome measure ONL thickness maps recorded at 32–38 wk.
Representative ONL maps show retention of thickness corre-
sponding to the injection bleb for the two highest titers compared
with lack of such effect for the lowest titer (Fig. 2A). Quantitative
analysis of all eight eyes of five animals (Table S1) showed that the
regions injected with a vector titer of 1.51 × 1011 vg/mL had an
ONL thickness closest to WT (Fig. 2B). Injection volumes at 5 wk
of age were 70 μL, which is a total vector dose of 10.6 × 109 vg.
Lower titers resulted in ONL thickness expected from the un-
treated XLPRA2 natural history, and a higher titer did not reach
theWT thickness, although it did show an effect of treatment (Fig.
2B). Thus, we consider the titer of 1.51 × 1011 vg/mL as the MET
to a first approximation. Transgene expression was specifically
detected by immunohistochemistry on retinal sections using an
antibody (Table S2) that recognizes human but not canine RPGR
protein. Immunolabeling was found exclusively in the bleb area,
and semiquantitative assessment showed that the level of expres-
sion of the stable hRPGR variant was dose dependent. At the
highest titers, the transgene was found throughout the length of the
photoreceptors (with the exception of the outer segments; Fig. 2C)
as previously reported when using retinal tissues fixed in para-
formaldehyde for >1 h (30, 31). Immunolabeling of the RPGR
transgene product has been shown to be restricted to the connecting
cilium only when using a modified short (1–2 min) paraformaldehyde
fixation protocol (31, 34). Importantly, control injections (n = 7)
performed with balanced salt solution (BSS) in XLPRA2 eyes at
different ages resulted in no measurable deviation of ONL thickness
from the expected natural history (Fig. S1 D and E).
To determine whether there was toxicity of the vector to the
retina, adult-size WT canine eyes were injected over a 2 log10
range of titers (Fig. S2), with a higher volume (150 μL) to cover a
similar retinal area as achieved with 70 μL at 5 wk of age. For the
MET and lower titer, the bleb region in WT eyes did not show a
detectable difference from the surrounding uninjected region in
Fig. 1. Schematic of neurodegenerations and complex spatiotemporal in-
teractions of potential treatments that seek to prevent disease or positively
modify the natural history in retinitis pigmentosa. (A) Natural history of neu-
ron death can be approximated as a delayed exponential function (Upper).
Therapies initiated at intermediate stages aim to stop further neuron loss and
rescue function (Lower). (B) In retinitis pigmentosa and allied diseases, there is
a complex spatial distribution of photoreceptor degeneration. Typically an
annulus is affected first, and over decades, the width of the annulus grows
both centrifugally and centripetally (Upper). Subretinal gene therapy in-
jections aim to modify the natural history locally by either preventing or ar-
resting neurodegeneration depending on the local disease stage (Lower).
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terms of ONL thickness. At the highest titer, however, there was
evidence of mild ONL thickening at and around the bleb region in
WT retinas (Fig. S2 A and B). Histology was not available, and mild
toxicity of WT retinas to the vector at the titer of 15.1 × 1011 vg/mL
cannot be ruled out; the significance of this finding to the mutant
eyes is currently not clear. Taking all of the XLPRA2 and WT re-
sults into consideration, the remaining experiments were performed
with the 1.51 × 1011 vg/mL titer of the AAV2/5 vector carrying a
stable hRPGR transgene under the control of the hIRBP promoter.
Intervention at Initial Disease Stage Arrests Photoreceptor Loss and
Rescues Vision for 3+ Y. Long-term durability of the therapeutic ef-
fect of intervention at the time that degeneration begins was eval-
uated next. An XLPRA2 retina was injected with MET at 5 wk of
age, and ONL thickness across a wide extent of retina was mapped
serially between 32 and 131 wk (Fig. 2D). Even at the first time
point (27 wk after treatment), ONL thickness within the treated
region was significantly thicker than the surrounding untreated re-
gion. Over the next 2 y, the untreated region lost ONL thickness
along the trajectory consistent with the expected natural history of
degeneration, whereas the injected region stably retained ONL
thickness close to WT values (Fig. 2D). The difference in ONL
thicknesses between the treated region and the surrounding un-
treated region progressively increased with time. Retinal function
with full-field electroretinography (ERG) showed in the treated
eye retention of rod and cone function up to the latest test date at
157 wk of age (Fig. S3A, Left). In the contralateral BSS-injected
eye, rod function was not detectable and cone function was severely
reduced. Visual function was assessed in an obstacle-avoidance
course at 130–164 wk of age. Significantly improved navigation
performance (shorter transit time and reduced number of col-
lisions) under scotopic and low mesopic ambient illumination
(≤0.2 lx) was observed when testing the treated eye in compar-
ison with the untreated eye; treated eye results were within the
range observed with WT dogs (Fig. S3B, Left).
Gene Therapy Intervention at Mid-Stage Disease Arrests Photoreceptor
Loss and Rescues Vision for Up to 3 Y. The stability of rescue fol-
lowing intervention at mid-stage disease was evaluated next.
XLPRA2 retinas were injected with MET at 12 wk of age (volume
injected: 150 μL; dose: 22.7 × 109 vg), after the peak of photo-
receptor cell death that results in a loss of ∼40% of the ONL (29).
ONL thickness across a wide extent of retina was mapped serially
between 31 and 131 wk (Fig. 3 A and B). Although ONL maps at
the first time point (31 wk of age, 19 wk after treatment) suggested
some rescue in the treated region, this was more evident at later
time points (Fig. 3A and Fig. S4A). In three treated XLPRA2
dogs, both in the superior and inferior retina, measurements of
Fig. 2. Dose–response function and long-term durability of gene therapy intervention at initial disease stage. (A) Pseudocolor maps of mean ONL thickness to-
pography in wild-type dogs (n = 5; ages 7–43 wk; mean = 25 wk) compared with individual eyes of representative XLPRA2 dogs (at 36–38 wk) subretinally treated at
5 wk of age in the supero-nasal quadrant with 70 μL of different vector titers. Dashed outline, the retinal region corresponding to the subretinal bleb. All eyes shown
as equivalent right eyes and optic nerve and major blood vessels overlaid for ease of comparison. T, temporal; N, nasal retina. (B) ONL thickness fraction of WT (log10
units) at 36–38 wk of age as a function of vector titer injected at 5 wk. Data from treated (Tx, green) and untreated (UnTx, red) retinal regions are contrasted. The
ranges of ONL fraction expected in WT eyes (thin dashed) or in untreated XLPRA2 eyes at 38 wk of age (thick dashed) are shown. In B and D, smaller symbols
represent the individual data and larger symbols with error bars represent mean ± SD; *P < 0.01 for paired t tests. (C) Immunolabeling of stable human RPGR
transgene product on retinal sections at 43 wk of age (38 wk after treatment) is found exclusively in the photoreceptors at the bleb/treated areas and is dose
dependent. (D) Serial ONL thickness measures between 32 and 131 wk of age after a superior subretinal vector injection at 5 wk of age (green arrow) to evaluate
long-term durability with the 1.51 × 1011 vg/mL titer. Treated loci (green) remain nearWT thickness (thin dashed lines), whereas untreated loci (red) show progressive
thinning along the trajectory expected from the natural history of disease (thick dashed lines). Z468-OS and similar labels designate the individual animal and eye.
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ONL thickness on each side of the treatment border showed an
initial decline that followed the natural course of disease, but
ONL loss in the treated region was halted at 31 wk of age. The
rescue persisted up to 131 wk of age, the latest evaluation point.
Histological assessment in an XLPRA2 dog at 113 wk of age
confirmed the in vivo imaging results with a clear demarcation in
ONL thickness at the border of the bleb (Fig. 3C). There was a
substantially thicker ONL in the treated (approximately seven
rows of nuclei) vs. untreated (approximately one to three rows of
nuclei) regions. Inner (IS) and outer (OS) segments of photore-
ceptors had a normal appearance within the treated area, but they
were almost completely lost in the untreated region (Fig. 3D).
Fig. 3. Efficacy and long-term stability of gene therapy intervention at mid-stage disease. (A) Pseudocolor maps of ONL thickness topography at 31 and 105 wk of
age in an XLPRA2 dog treated at 12 wk of age. Dashed outline, the retinal region corresponding to the subretinal vector bleb at treatment. Schematic, right, paired
loci across the treatment boundary and in the inferior retina chosen for quantitative evaluation. Eyes are shown as equivalent right eyes with optic nerve and major
blood vessels overlaid for ease of comparability. T, temporal; N, nasal retina. (B) Progressive changes in ONL fraction recorded serially between 11 and 130wk of age in
treated (green) and untreated (red) loci in the superior (Left) and inferior (Right) retinas of three XLPRA2 dogs. Vertical green arrows depict the timing of treatment at
12 wk of age. Dashed lines show the range of ONL fraction expected inWT eyes or natural history of progression in untreated XLPRA2 eyes. Smaller symbols represent
the individual data and larger symbols with error bars represent mean ± SD; *P < 0.01 for paired t tests between treated and untreated loci. (C–G) Retinal morphology
at 113 wk of age in the untreated (Left) and treated (Right) areas of an XLPRA2 dog injected at 12 wk. (C) H&E-stained section across the treatment boundary (red bar
in diagram shows section location). (D) H&E stain, higher magnification view. (E) IHC labeling of stable human RPGR transgene product. (F) Cone arrestin (CA, red) and
rhodopsin (RHO, green) double IHC. (G) R/G opsin (red) IHC labeling. Z463-OS and similar labels designate the individual animal and eye.
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Expression of the stable human RPGR transgene product was
localized exclusively to photoreceptors of the treated area (Fig.
3E) and was found throughout the cell except in the OS (30).
Immunolabeling with cone arrestin and rod and cone opsin anti-
bodies confirmed the structural rescue of both photoreceptor
populations (Fig. 3F), as well as the reversal of opsin mis-
localization (Fig. 3 F and G) in the treated area. Not only was
cone structure better preserved, but counts of total (M/L and S)
cones showed a higher number of cells in the treated relative to
untreated areas, and approximately twice as many S cones were
found to express S opsin in their OS (Fig. S5 A and B). To de-
termine the effect of RPGR augmentation on the structure of the
photoreceptor sensory cilium, three ciliary markers (rootletin,
centrin-3, and acetylated α-tubulin) were used for IHC. Their
pattern of labeling in the treated area was normal (Fig. S5C) and
similar to that seen in an untreated XLPRA2 at the injection age
of 12 wk (Fig. S6 A and B), but very different from the reduced
immunostaining in the untreated area at 113 wk (Fig. S5C). Thus,
mutant retina treated by RPGR augmentation retained molecular
components of the sensory cilium to their normal site and levels of
expression. Overall, these results suggest that intervention at
mid-stage disease is able to stop cell death. Based on the obser-
vation that rod and cone IS and OS structure in treated 113-wk-old
animal (Fig. 3 C and D) is more normal than at the 12 wk of age,
the injection time point (Fig. S6B; H&E), there appears to be
preliminary evidence that treatment could actually reverse struc-
tural alterations in the surviving photoreceptors. Further support
comes from restoration of normal dendritic arborization of ON
bipolar cells located within the treated area (Fig. S5D). In the
treated eyes of two dogs, ERG showed retained rod and cone
function up to the latest test date at 157 wk of age (Fig. S3A,
Center). Visually guided behavior in an obstacle avoidance course
was also significantly improved under scotopic and mesopic ill-
lumination when testing the treated eyes between 130 and 164 wk
of age (Fig. S3B, Right).
Efficacy and Durability for Up to 2+ Y of Gene Therapy Intervention at
Late-Stage Disease. To assess whether the window for therapeutic
intervention could be extended to a more advanced disease
stage, XLPRA2 retinas were injected with MET at 26 wk of age.
At this age, the ONL is approximately four to five rows of nuclei
thick in the central/midperipheral retina (∼40–50% of normal),
and the structure of the OS is severely compromised (29). To-
pographic maps of ONL thickness from early postinjection
time points did not indicate a rescue effect for up to 40 wk (Fig.
4A and Fig. S4B). By 52 wk of age, a region of rescue became
qualitatively visible and statistically significant (Fig. 4B). From
that time point up to 131 wk of age, ONL loss was halted in the
treated area of the superior retina, but continued unabated in
the untreated region (Fig. 4 A and B and Fig. S4B). This rescue
was confirmed histologically in an XLPRA2 dog at 113 wk of
age. The ONL was thicker in the treated (approximately four rows
of nuclei) than in the untreated (approximately one to two rows of
nuclei) region, and photoreceptors retained the normal elongated
IS and OS (Fig. 4 C and D). Expression of the stable human
RPGR transgene in the treated areas (Fig. 4E) was associated with
better preserved rod and cone OS structure and with correction of
rod opsin mislocalization (Fig. 4 F and G). An increase in the
number of all cones (M/L + S), as well as S cones with preserved
OS, was found in the treated vs. untreated area (Fig. 5 A and B).
The immunolabeling pattern of the photoreceptor sensory cilium
was also better preserved in the treated area at 113 wk of age (Fig.
5C) and resembled that seen in an untreated dog at 24 wk of age
(Fig. S6C). The presence of inner retinal gliosis was assessed by
GFAP immunolabeling and did not reveal any increased reactivity
of astrocytes or Müller cells in either the treated or untreated
areas. Finally, rod bipolar cells reestablished the dendritic arbor-
izations that were absent at the 26-wk injection time point (29),
and had completely retracted in the untreated regions at 113 wk of
age (Fig. 5D). ERG analysis performed at 105 wk of age showed
preserved rod function in all three dogs and cone function in two
of three animals as illustrated for dog Z465 (Fig. 6A). Although in
the third dog (Z464) similar amplitudes of persistent cone function
were recorded from both the treated and untreated eye, combined
analysis of the ERG data from all three dogs showed a statistically
significant positive rescue of rod-mediated retinal function (Fig.
6B). The mean ERG values at 105 wk of age from the three treated
dogs were compared with that of seven WT adult dogs and showed
that rod-mediated b-wave amplitude was 8% of WT, and mixed
rod-cone a- and b-wave amplitudes were, respectively, 6% and
11% of WT. Because at 26 wk of age the XLPRA2 retina has lost
50–60% of its photoreceptors (primarily rods) and only ∼1/5 of the
retina was treated, these values suggest that maximal achievable
ERG preservation was obtained from the treated area. ERG
measurements repeated at 157 wk of age (latest test date) in the two
remaining XLPRA2 dogs showed persistent rescue of both rod and
cone function in the treated eyes (Fig. S3A, Right). Combined
analysis of the performance of these two dogs in an obstacle-
avoidance course between 130 and 164 wk of age showed a faster
transit time (within the range of WT dogs) and reduced number of
collisions when testing the treated vs. the untreated eyes under
scotopic and mesopic ambient illumination. Visual function was
further investigated in these animals between 149 and 162 wk of age
by assessing their ability to detect a dim blue flashing light in a
forced two-choice Y maze (Fig. S7). An improved ability to detect
the light stimulus was seen when testing the treated eyes. Combined
analysis of the data collected from both dogs during all eight ses-
sions showed a statistically significant difference in the success rate
of the treated vs. untreated eye (91% vs. 63%; P < 0.001; Fig. 6D).
Discussion
Inherited retinopathies are Mendelian diseases caused by thou-
sands of mutations in >200 distinct genes (18). Most commonly,
there is a progressive loss of vision due to neurodegeneration of
retinal photoreceptors, and there is no cure or treatment (35).
Potential therapeutic approaches can be categorized into three
groups: (i) prevention of degeneration before it starts, (ii) slowing
the rate of progression, and (iii) replacement of lost photore-
ceptors and their intraretinal connectivity (35). In the current
work, we used an AAV2/5 vector to intervene with gene aug-
mentation therapy both early and late in a naturally occurring
canine model of RPGR-XLRP and demonstrated long-lasting ar-
rest of retinal degeneration, restoration of normal structure in the
remaining photoreceptors and bipolar cells, and rescue of vision.
Defining the Natural History of Disease as a Prelude to Interventions at
Different Stages. In human clinical trials to date, AAV-vectored
gene therapy for the RPE65 form of Leber congenital amaurosis
(LCA) has shown improvement of some aspects of vision (36, 37),
but there is recent evidence in patients from two of the ongoing
trials that such intervention has not been able to stem the pro-
gression rate of retinal degeneration (16, 38, 39). In naturally
occurring canine models, both of RPE65-LCA and others, gene
therapy has produced similar results: intervention after the onset
of photoreceptor degeneration has not been able to modify the
natural history of the disease (16) or to restore visual function
unless adjunctive treatments are done (40). When the intervention
preceded major loss of photoreceptors, prevention of retinal degen-
eration has often been achieved (16, 30, 41, 42) but not always (17).
In mice, there is an extensive literature on gene augmentation
therapy showing improved photoreceptor survival as long as the
intervention is applied before or at very early stages of retinal de-
generation (43–47). Other work has shown positive effects of gene
therapy when applied to disorganized retinas with rosettes (48).
Successful rescue of photoreceptors with gene augmentation has
been difficult to achieve when applied late in the disease natural
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history. There have been reports of success (31, 49, 50) but with the
caveat of a lack of quantitative definition of spatiotemporal natural
history of retinal degeneration at the time of the intervention.
It is well known that human retinopathies demonstrate very
complex spatiotemporal patterns of disease progression (Fig. 1B)
(51, 52), even though underlying genetic mutations are presumed to
be expressed in all retinal cells of relevance. In mouse models, and
their localized treatments with gene therapy, spatiotemporal gra-
dients of natural disease progression are not often investigated.
However, when carefully examined, there can be major gradients of
ONL thickness that significantly varies within and between retinas
(23). Therefore, we first quantitatively defined the spatiotemporal
natural history of retinal degeneration in the XLPRA2 dogs
(Fig. S1). Both in the superior and inferior retina loci, exponential
functions (16) with different parameters described the progressive
loss of photoreceptors for the first 1.5 y of life. Extrapolating the
Fig. 4. Efficacy and long-term durability of gene therapy intervention at late-stage disease. (A) Pseudocolor maps of ONL thickness topography at 40 and 106 wk
of age in an XLPRA2 dog treated at 26 wk of age. Dashed outline, the retinal region corresponding to the subretinal vector bleb at treatment. Schematic, right,
paired loci across the treatment boundary and in the inferior retina chosen for quantitative evaluation. Eyes are shown as equivalent right eyes with optic nerve
and major blood vessels overlaid for ease of comparability. T, temporal; N, nasal retina. (B) Progressive changes in ONL fraction recorded serially between 25 and
130 wk of age in treated (green) and untreated (red) loci in the superior retina (Left). None of the three treated eyes received injection in the inferior retina; thus,
only untreated loci are shown in inferior retina (Right). Vertical green arrows depict the timing of treatment at 26 wk of age. Dashed lines show the range of ONL
fraction expected in WT eyes or natural history of progression in untreated XLPRA2 eyes. Smaller symbols represent the individual data and larger symbols with
error bars represent mean ± SD; *P < 0.01 for paired t tests between treated and untreated loci. (C–G) Retinal morphology at 113 wk of age in the untreated (Left)
and treated (Right) areas of an XLPRA2 dog injected at 26 wk. (C) H&E-stained section across the treatment boundary (red bar in diagram shows section location).
(D) H&E stain, higher magnification view. (E) IHC labeling of stable human RPGR transgene product. (F) Cone arrestin (CA, red) and rhodopsin (RHO, green)
double IHC. (G) R/G opsin (red) IHC labeling. Z465-OD and similar labels designate the individual animal and eye.
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natural history to young ages implied an initial delay of degeneration
that likely ranged from 5 to 12 wk of life and varied by location and
animal. The rate of degeneration was slower in the superior and
supero-nasal retina (−0.33 log10/y) compared with the inferior retina
(−0.45 log10/y).
Comparability of Progression of Disease in the Canine and Human. In
patients with RPGR-XLRP, the exact spatiotemporal natural his-
tory of retinal degeneration is not known: this lack of knowledge
extends to all other molecular forms of RP. There are, however,
published estimates of rates of vision loss in RPGR-XLRP, and
these can be used to estimate underlying retinal degeneration.
For example, ERG amplitudes have been shown to change by
−0.07 log10/y for cones and rods (53). These full-field averaged
values are in the same order of magnitude as psychophysical
sensitivity changes rates reported for cone vision ranging from
−0.06 to −0.09 log10/y at specific extramacular retinal locations
(54). Previous work has shown that rod and cone losses tend to be
equal in this condition (55). Under the simplifying assumptions of a
delayed exponential progression of disease (56) and a relationship
between the square of ONL thickness and light sensitivity (57), the
rate of ONL thickness change in human RPGR-XLRP can be
estimated to fall in the range of −0.03 to −0.05 log10/y. Using
allometric scaling based on maximum lifespan (26), the human
progression estimate corresponds to −0.18 to −0.31 log10 per ca-
nine-equivalent years, which is similar to the rate of −0.33 log10/y
estimated in the superior retina of XLPRA2 dogs but slower than
the −0.45 log10/y estimated in the inferior retina. Thus, the current
studies were performed to place the treatment injections in the
superior retinal locations whenever possible. Future studies of
human RPGR-XLRP should ideally include direct measurement of
the thickness of the photoreceptor layer and its progressive thin-
ning as we previously performed in RPE65-LCA (16) to provide a
quantitative and predictive spatiotemporal measure of the natural
history of degeneration in advance of upcoming treatment trials.
The Window of Opportunity for RPGR Gene Augmentation Can Be
Expanded to Later Stages of Retinal Degeneration. After demon-
strating the long-term (>3 y) stable rescue effect provided by early
gene therapy intervention, we focused our efforts on determining
Fig. 5. Structural rescue of photoreceptors and bi-
polar cells in a XLPRA2 dog treated at late-stage
disease. Histology at 113 wk of dog Z460 injected at
26 wk of age. (A) Mean (±SD) number of (M/L + S)
and S cones per millimeter of retina length in the
treated and untreated areas (n = 4). (B) S cone opsin
(green) IHC labeling in the untreated area (Left),
across the treatment boundary (Center), and in the
treated area (Right). The schematic drawing illus-
trates the treatment area (dashed black curve), and
the location of the section showing the treatment
boundary (red line). (C) IHC labeling of the sensory
cilium of photoreceptors with rootletin, centrin-3
(Cetn3), and acetylated α-tubulin antibodies. (D) Goα
IHC labeling of ON-bipolar cells. White arrowheads
point to their dendrites.
E5850 | www.pnas.org/cgi/doi/10.1073/pnas.1509914112 Beltran et al.
Fig. 6. Long-term durability of retinal function and visual behavior after gene therapy intervention at late-stage disease. (A) Representative ERG traces of rod
(−1.74 log cd·s·m−2), mixed rod-cone (1.01 log cd·s·m−2) recorded dark adapted, and cone (1.01 log cd·s·m−2) responses to single stimuli or 29-Hz cone flicker (0.76 log
cd·s·m−2) recorded light adapted at 105 wk of age in an XLPRA2 dog treated at 26 wk of age. (B) Summary of all rod and cone ERG results recorded at 105 wk of age
from three XLPRA2 dogs treated at late-stage disease. (C) Mean (±SD) transit time and mean (±SD) number of collisions in an obstacle-avoidance course under
different ambient light intensities. The treated vs. control eyes of two XLPRA2 dogs (Z464 and Z465) injected at 26 wk of age were compared after pooling data
recorded during nine trials conducted between 130 and 164 wk of age. Gray dotted lines represent the 95% CI of the transit time of WT dogs (n = 3). No collisions
were observed with these WT dogs. (D) Visually guided behavior in a forced two-choice Y maze of the same two XLPRA2 dogs treated at 26 wk of age. (Left and
Center) Performance of each dog when assessing the treated vs. the control eye during eight test sessions conducted between 149 and 162 wk of age. (Right) Visual
performance of the treated vs. control eyes after pooling together data from both dogs and from all eight sessions (total of 320 trials). *P < 0.05, **P < 0.001 from
paired Student t test (for ERG data) and from generalized linear model testing (for obstacle course and Y maze data) between treated and control eyes.
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whether RPGR gene augmentation could arrest the natural course
of disease when delivered at patient-relevant stages of retinal
degeneration. For this, XLPRA2 dogs at mid- and late-stage dis-
ease were subretinally injected with the same viral titer (1.51 ×
1011 vg/mL) as used at the initial stage (this study and ref. 30).
Because the numbers of photoreceptors are reduced by ∼50–60%
at 26 wk of age (late-stage intervention), the titer used would be
predicted to result in an approximately twofold higher vector load
per photoreceptor cell compared with dogs treated at 5 wk of age
with their full photoreceptor complement (initial-stage interven-
tion). No signs of ocular toxicity were detected clinically or his-
tologically even when treating XLPRA2 with a 10-fold higher viral
titer (15.1 × 1011 vg/mL) than that selected for the long-term
studies. This lack of toxicity suggests that the AAV construct used
may have a reasonably high therapeutic index. These results
contrast, however, with the findings from another group that
observed both short- and long-term toxicity in the Rpgr KO
mouse when using a different AAV serotype/promoter/RPGR
transgene at doses, respectively, 3- and 10-fold higher than the
one that provided the most potent therapeutic effect (31).
Following intervention at mid and late stages of disease, there
was a latency of up to 26 wk before the rate of ONL loss was
substantially altered. Such a “delay” in ONL rescue could be
explained by a lower efficiency of the vector at transducing older/
diseased photoreceptors or the inability for corrective gene
therapy to modify the fate of cells that are already irreversibly
damaged and committed to cell death. After ONL loss was
halted, the rescue effect was shown to be stable for more than 2 y
following intervention at late-stage disease. Histological assess-
ment in two dogs treated at mid and late stage confirmed the
morphological rescue of both rods and cones, correction of opsin
mislocalization, and reversal of the early dendritic retraction of
bipolar cells (29). The structural preservation of surviving photo-
receptors including their sensory cilium, and the positive remod-
eling of the inner retina was associated with improved ERG
amplitudes of rods, cones, and postreceptoral neurons in all
treated eyes. Significantly, we now demonstrate for the first
time to our knowledge that RPGR gene augmentation prolongs
rod-driven visual behavior, an observation that could not be
made at earlier time points when significant vision under sco-
topic illumination still persisted in the control eyes (30).
Improving the Predictive Value of Animal Models Used to Test
Treatments for Retinal Degeneration. Over the last decades,
several therapeutic strategies that include the use of neuro-
protective agents, antiapoptotic factors, immunotherapy, and
corrective gene therapy have been developed with the ulti-
mate goal of preventing or halting photoreceptor degenera-
tion. With few exceptions (31, 49, 50), preclinical evidence
gathered to support the initiation of clinical trials has been
based on proof-of-concept studies conducted in animal models
at a predegenerative stage (11, 58–61). A limitation is that these
experiments at predegenerate stages fail to recapitulate the
cellular and molecular environment of surviving photorecep-
tors in patients with advanced disease. So does drug develop-
ment for retinal degenerative diseases run a risk of high
attrition as seen with the therapy pipelines for Alzheimer and
Parkinson’s diseases (6, 7)? Disappointing results with sus-
tained delivery of the neuroprotective agent ciliary neuro-
trophic factor (CNTF) for the treatment of early- and late-
stage RP in two studies (62) and evidence that patients
involved in two of the gene therapy clinical trials for the
RPE65 form of Leber congenital amaurosis (LCA) show un-
abated photoreceptor and vision loss despite initial visual
improvement (16, 38, 39) suggest that evidence in animal
models for long-term efficacy and testing at clinically relevant
stages of disease are needed to improve the predictive value
of preclinical studies.
In conclusion, although regulatory agencies such as the US
Food and Drug Administration, which are responsible for ap-
proving investigations of new drugs in humans, require pre-
clinical data from animal pharmacology and toxicology studies,
there has been a poor “return on investment” of many drug trials
for neurodegenerative diseases. This situation calls for reconsi-
dering the importance of establishing proof of concept in animal
models that truly recapitulate the stages of disease of patients to
be enrolled in phase II/III clinical trials. Despite the increased
financial pressure that this would exercise on both academia and
industry, this appears to be a necessary step to increase the success
rate in translating new drugs to the clinical phase. For retinal gene
therapy approaches, this would involve confirming efficient trans-
duction of targeted cells in an animal that models the various human
stages of degeneration and positive alteration of the natural course
of disease before filing an Investigational NewDrug application. Our
successful late-stage intervention and long-term follow-up results in a
clinically relevant large animal model now provide the necessary
proof of concept to support a clinical trial for RPGR-XLRP.
Materials and Methods
All dogs were bred and maintained at the University of Pennsylvania Retinal
Disease Studies Facility (RDSF). The studies were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health (63) and the USDA’s Animal Wel-
fare Act and Animal Welfare Regulations and complied with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research. The protocols
were approved by the Institutional Animal Care and Use Committee of the
University of Pennsylvania. RPGR mutant (XLPRA2) (28, 29) and WT dogs were
used to characterize the natural course of ONL thinning as a function of age
(16) and the response to subretinal injections with an AAV2/5 vector (64) car-
rying a stabilized human RPGR1-ORF15 cDNA under the control of a human IRBP
promoter (30, 65). The stabilized human RPGR1-ORF15 cDNA (stable hRPGR)
contained seven in-frame deletions, one 3-bp insertion, and 65-bp sub-
stitutions spread throughout the AG-rich region of exon ORF15 compared
with the published (GenBank: NM_001034853) human RPGR1-ORF15 sequence
(34). Stable hRPGR was the same sequence as used in our previous RPGR gene
augmentation study in XLPRA1 and XLPRA2 dogs (30). Assessment of the re-
sponse to RPGR gene transfer was made by means of clinical ophthalmic
examinations, en face and cross-sectional in vivo retinal imaging (Fig. S8), elec-
troretinography, visual behavior testing that included the use of an obstacle-
avoidance course and a forced 2-choice Ymaze, andmorphological evaluation on
retinal histological section (16, 29, 30, 61). Methodological details are provided in
SI Materials and Methods.
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